FH-TCR-Tᴍsʟɴ / Fred Hutchinson Cancer Center - LARVOL DELTA

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P1 | N=9 | Terminated | Sponsor: Fred Hutchinson Cancer Center | Trial completion date: Sep 2025 ➔ Jan 2025 | Active, not recruiting ➔ Terminated; Study terminated due to end of funding.

Trial completion date • Trial termination • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • HLA-A • MSLN

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: Fred Hutchinson Cancer Center | Recruiting ➔ Active, not recruiting | N=15 ➔ 9

Enrollment change • Enrollment closed • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • HLA-A • MSLN

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Trial primary completion date: Jun 2024 ➔ Dec 2024

Metastases • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • HLA-A • MSLN

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Trial completion date: Sep 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2023 ➔ Jun 2024

Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • HLA-A • MSLN